GRCE.US Grace Therapeutics, Inc.

Healthcare Pharmaceuticals USA Stocks
1.81 USD
Close of Nov 14, 2026
1.67 5.18
Market cap
USD 38.1M
P/E
-
P/B
0.79x
ROE
-64.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is GRCE.US undervalued?

Graham number

The Graham number of Grace Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Grace Therapeutics, Inc. fundamental analysis

No fundamental analysis for Grace Therapeutics, Inc. yet.

Grace Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Grace Therapeutics, Inc.

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the…

Full company profile